Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451071 · ClinicalTrials.gov registry record · Phase 4
Postpartum HPV Vaccination
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 195
- Enrollment target
NCT03451071: Completed Phase 4 study, sponsored by University of Alabama at Birmingham.
NCT03451071 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 195 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451071, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 195 participants
- Enrollment target
Study Summary
Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore, greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer disproportionately affects women of color in both incidence and mortality. Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine. The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations. However, data show that the immune response in young women is less robust than in adolescents, and no studies have examined immunogenicity in postpartum women specifically. We propose an HPV vaccination pilot study in women who receive postpartum care at University of Alabama at Birmingham (UAB) hospital. We will examine the acceptability, uptake and immunogenicity of the vaccine in the postpartum setting.
Primary Outcome
This was established using a survey to indicate willingness to receive vaccine.
Interventions
- DRUG Gardasil9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2020-12-30 |
| Phase | Phase 4 |
What the finished NCT03451071 record still lists
NCT03451071 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Gardasil9 is the first listed.
NCT03451071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03451071 about?
NCT03451071 is a clinical study titled "Postpartum HPV Vaccination". Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore, greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer disproportionately affects women of color in both incidence and mortality. Due to low HPV vaccine uptake in the US, inn...
What is the current status of trial NCT03451071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 195 participants. The study started on 2019-04-29. Estimated completion is 2020-12-30.
What interventions are being tested in trial NCT03451071?
The interventions under investigation include: Gardasil9 (DRUG).
Who is sponsoring clinical trial NCT03451071?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03451071's enrollment target sits among peer trials
195 450th of 2000 higher than 1,550 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI